Form 4: Rigel Pharmaceuticals Director Brian L. Kotzin Reports Acquisition and Disposal of Securities

Director Brian L. Kotzin reports acquisition of 25,000 shares of common stock and disposal of 100,000 shares, along with acquisition of options to buy 30,000 shares, in Rigel Pharmaceuticals.

Summary

• On May 25, 2024, Brian L. Kotzin, a director of Rigel Pharmaceuticals, reported acquiring 25,000 shares of common stock through the vesting of restricted stock units.
• Kotzin also disposed of 100,000 shares of common stock.
• Additionally, Kotzin acquired options to purchase 30,000 shares of common stock at an exercise price of $0.9075, exercisable starting May 25, 2024, and expiring on May 25, 2034.
• The stock options vest monthly over one year, contingent upon continuous service on the Board of Directors.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing transactions by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about stock and option transactions.

Future Outlook

The restricted stock units will fully vest on the date prior to the Company's next Annual Meeting, subject to continuous service on the Company's Board of Directors. The stock options vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future stock performance.

Stakeholder Impact

• The transactions may influence shareholder perception of the company's stock.

Key Dates